Assessment of target-mediated biodistribution of an 89Zr labeled PD-L1/4-1BB bispecific Mabcalin protein

被引：0
|
作者：
van Winkel, Claudia A.
Fan, Xiaoyu
Giesen, Danique
Gauderat, Glenn
Pattarini, Lucia
Jaquin, Thomas
Barakat, Anissa
De La Bigne, Anne-Marie
Richter, Marleen
Andersen, Nicole
Legrand, Julie
Lelievre, Helene
de Vries, Elisabeth G.
Morales-Kastresana, Aizea
Lub-de Hooge, Marjolijn N.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-3579
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3579
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Characterization of a Trispecific PD-L1 Blocking Antibody That Exhibits EGFR-Conditional 4-1BB Agonist Activity
    Rubio-Perez, Laura
    Frago, Susana
    Compte, Marta
    Navarro, Rocio
    Harwood, Seandean L.
    Lazaro-Gorines, Rodrigo
    Gomez-Rosel, Marina
    Hangiu, Oana
    Silva-Pilipich, Noelia
    Vanrell, Lucia
    Smerdou, Cristian
    Alvarez-Vallina, Luis
    ANTIBODIES, 2024, 13 (02)
  • [32] Targeting 4-1BB and PD-L1 induces potent and durable antitumor immunity in B-cell lymphoma
    Wang, Yichen
    Zhang, Xuyao
    Xu, Caili
    Nan, Yanyang
    Fan, Jiajun
    Zeng, Xian
    Kwon, Byoung S.
    Ju, Dianwen
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [33] PET imaging of radiation-induced PD-L1 upregulation in the tumor microenvironment using a Zr-89 labeled PD-L1 monoclonal Ab in a mouse model
    Kikuchi, Masahiro
    Srivastava, Raghvendra
    Sun, Lingyi
    Zeng, Dexing
    Diaz-Perez, Julio
    Anderson, Carolyn
    Ferris, Robert
    Edwards, W. Barry
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58
  • [34] Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
    Muik, Alexander
    Garralda, Elena
    Altintas, Isil
    Gieseke, Friederike
    Geva, Ravit
    Ben-Ami, Eytan
    Maurice-Dror, Corinne
    Calvo, Emiliano
    LoRusso, Patricia M.
    Alonso, Guzman
    Rodriguez-Ruiz, Maria E.
    Schoedel, Kristina B.
    Blum, Jordan M.
    Sanger, Bianca
    Salcedo, Theodora W.
    Burm, Saskia M.
    Stanganello, Eliana
    Verzijl, Dennis
    Vascotto, Fulvia
    Sette, Angelica
    Quinkhardt, Juliane
    Plantinga, Theo S.
    Toker, Aras
    van den Brink, Edward N.
    Fereshteh, Mark
    Diken, Mustafa
    Satijn, David
    Kreiter, Sebastian
    Breij, Esther C. W.
    Bajaj, Gaurav
    Lagkadinou, Eleni
    Sasser, Kate
    Tureci, Ozlem
    Forssmann, Ulf
    Ahmadi, Tahamtan
    Sahin, Ugur
    Jure-Kunkel, Maria
    Melero, Ignacio
    CANCER DISCOVERY, 2022, 12 (05) : 1248 - 1265
  • [35] Dose-dependent targeting of 89Zr-labeled atezolizumab (anti-PD-L1 antibody) to PD-L1 expressing tumor xenografts
    Longtine, Mark
    Wahl, Richard
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59
  • [36] Engineering of a trispecific tumor-targeted immunotherapy incorporating 4-1BB co-stimulation and PD-L1 blockade
    Warmuth, Stefan
    Gunde, Tea
    Snell, Daniel
    Brock, Matthias
    Weinert, Christopher
    Simonin, Alexandre
    Hess, Christian
    Tietz, Julia
    Johansson, Maria
    Spiga, Fabio Mario
    Heiz, Robin
    Fluckiger, Naomi
    Wagen, Sandro
    Zeberer, Julia
    Diem, Dania
    Mahler, Dana
    Wickihalder, Belinda
    Muntwiler, Simone
    Chatterjee, Bithi
    Kuttner, Benjamin
    Bommer, Bettina
    Yaman, Yasemin
    Lichtlen, Peter
    Urech, David
    ONCOIMMUNOLOGY, 2021, 10 (01):
  • [37] 89Zr-Labeled Anti-PD-L1 Antibody PET Monitors Gemcitabine Therapy-Induced Modulation of Tumor PD-L1 Expression
    Jung, Kyung-Ho
    Park, Jin Won
    Lee, Jin Hee
    Moon, Seung Hwan
    Cho, Young Seok
    Lee, Kyung-Han
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62 (05) : 656 - 664
  • [38] A phase 1, dose escalation/dose-expansion study of QLF31907, a bispecific antibody (BsAb) targeting PD-L1 and 4-1BB, in patients with advanced solid tumors and lymphoma
    Lin, Tongyu
    Liu, Bin
    Pu, Xingxiang
    Wu, Lin
    Du, Xiaobo
    Mo, Ning
    Song, Zhengbo
    Zhou, Liwei
    Duan, Xianlin
    Zhu, Yanan
    Kang, Xiaoyan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [39] Batf3+DCs and the 4-1BB/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1/PD-L1 blockade efficacy
    Ziblat, Andrea
    Horton, Brendan L.
    Higgs, Emily F.
    Hatogai, Ken
    Martinez, Anna
    Shapiro, Jason W.
    Kim, Danny E. C.
    Zha, Yuanyuan
    Sweis, Randy F.
    Gajewski, Thomas F.
    CELL REPORTS, 2024, 43 (05):
  • [40] Immuno-PET using Zirconium-89 (89Zr) radiolabeled fully human anti-PD-L1 antibody successfully images PD-L1 positive tumors in preclinical mouse models
    Kelly, Marcus
    Giurleo, Jason
    Makonnen, Sosina
    Hickey, Carlos
    Arnold, T. Cody
    Ma, Dangshe
    Dai, Jie
    Pei, Jerry
    Tavare, Richard
    Kirshner, Jessica
    Olson, William
    Thurston, Gavin
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58
12345